A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma

INTRODUCTION: The PD-1 inhibitors have shown good response in the treatment for many types of malignant tumors, but as monotherapy for advanced esophageal squamous carcinoma, the objective response rate is low. Here we report a case of the patient with advanced esophageal squamous cell carcinoma (ES...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Yong, Ou, Zhu’an, Yao, Zhifang, Qiao, Guibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783208/
https://www.ncbi.nlm.nih.gov/pubmed/31577707
http://dx.doi.org/10.1097/MD.0000000000017164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783208/
https://www.ncbi.nlm.nih.gov/pubmed/31577707
http://dx.doi.org/10.1097/MD.0000000000017164

Ejemplares similares